Catholic Health Services takes part in Covid-19 clinical trials

Catholic Health Services is taking part in two clinical trials designed to develop treatments for Covid-19. A Mayo Clinic trial is using what is called convalescent plasma donated by recovered Covid-19 patents to treat individuals who continue to fight the coronavirus. Convalescent plasma is components from the blood of people who have had the virus and recovered.

The second study involves using the medication remdesivir that was originally developed to treat the Ebola virus and has been successfully used for other coronaviruses including Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome.

The convalescent plasma study is being offered at CHS’s six hospitals. The remdesivir trial is taking place at St. Francis Hospital, The Heart Center^® in Roslyn and at Good Samaritan Hospital Medical Center in West Islip, CHS officials said.

One 200 milliliters/6.8 ounces dose of the plasma has benefitted a portion of patients, according to the initial data. People who recover from Covid-19 do so, in part, because their blood contains antibodies that are able to fight the virus. Previous research of other viruses found that treating patients with plasma obtained from those who have recovered from the same virus leads to rapid improvement, CHS officials said.

Using remdesivir to treat COVID-19 follows limited testing in the United States, Canada, China and other countries that led to an improvement in the condition of some patients. The treatment regimen using remdesivir takes place over 10 days and includes a 200-milligram dose on the first day and a 100-milligram dose on days two to 10.

“Catholic Health Services is excited to be on the front lines and participate in these clinical trials for Covid-19,” CHS Senior Vice President and Chief Quality Officer Dr. Jason Golbin, stated in a news release. “Our clinical teams have spent several weeks caring for Covid-19 patients. It means a great deal to everyone to take part in these two cutting-edge research efforts.”  

Potential plasma donors must have a prior, verified diagnosis of Covid-19, but are now symptom-free and fully recovered. Donors must also be at least 18 and weigh at least 110 pounds. The plasma can be administered only to a consenting Covid-19 patient or a patient whose family member offers consent. The treatment will be given to patients judged by a doctor to be at high risk of disease progression to severe or life-threatening.

To donate plasma and for more information on the two clinical trials, call Catholic Health Services at (855) 247-4500.